Concepts (82)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2024 | 375 | 2.820 |
Why?
|
| Insurance Claim Review | 2 | 2023 | 41 | 1.170 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 53 | 1.090 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2024 | 763 | 1.010 |
Why?
|
| Cancer Survivors | 2 | 2022 | 85 | 0.920 |
Why?
|
| Lymphoma, T-Cell | 1 | 2023 | 48 | 0.900 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2023 | 35 | 0.900 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 44 | 0.890 |
Why?
|
| Lymphoma | 1 | 2023 | 262 | 0.810 |
Why?
|
| Psychotherapy, Brief | 1 | 2021 | 10 | 0.810 |
Why?
|
| Neoplasms | 3 | 2022 | 2898 | 0.630 |
Why?
|
| Health Care Costs | 2 | 2023 | 239 | 0.400 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2023 | 878 | 0.400 |
Why?
|
| Adolescent | 5 | 2024 | 8984 | 0.380 |
Why?
|
| United States | 4 | 2024 | 6681 | 0.300 |
Why?
|
| Humans | 19 | 2024 | 86678 | 0.270 |
Why?
|
| Retrospective Studies | 5 | 2024 | 8496 | 0.240 |
Why?
|
| Aniline Compounds | 1 | 2023 | 55 | 0.230 |
Why?
|
| Aminopyridines | 1 | 2023 | 38 | 0.230 |
Why?
|
| Triazines | 1 | 2023 | 53 | 0.230 |
Why?
|
| Adult | 7 | 2024 | 25659 | 0.230 |
Why?
|
| Pyrazines | 1 | 2023 | 92 | 0.230 |
Why?
|
| Survivors | 2 | 2022 | 226 | 0.230 |
Why?
|
| Costs and Cost Analysis | 1 | 2023 | 153 | 0.220 |
Why?
|
| Blood Platelet Disorders | 1 | 2022 | 9 | 0.220 |
Why?
|
| Health Resources | 1 | 2023 | 76 | 0.220 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2022 | 20 | 0.210 |
Why?
|
| Lymphoma, B-Cell | 1 | 2022 | 103 | 0.200 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 567 | 0.200 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 238 | 0.200 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 365 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2024 | 381 | 0.190 |
Why?
|
| Acute Disease | 1 | 2022 | 826 | 0.180 |
Why?
|
| Self Report | 1 | 2021 | 288 | 0.180 |
Why?
|
| Pilot Projects | 1 | 2021 | 840 | 0.160 |
Why?
|
| Hyperbilirubinemia | 1 | 2018 | 20 | 0.160 |
Why?
|
| Carnitine | 1 | 2018 | 14 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 372 | 0.160 |
Why?
|
| Asparaginase | 1 | 2018 | 35 | 0.160 |
Why?
|
| Immunotherapy | 1 | 2023 | 629 | 0.160 |
Why?
|
| Hospitalization | 1 | 2023 | 851 | 0.160 |
Why?
|
| Depression | 1 | 2021 | 473 | 0.160 |
Why?
|
| Young Adult | 4 | 2024 | 5980 | 0.150 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2018 | 69 | 0.150 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 1195 | 0.150 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 364 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 2438 | 0.130 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2023 | 127 | 0.110 |
Why?
|
| Female | 4 | 2023 | 44550 | 0.110 |
Why?
|
| Male | 3 | 2023 | 40988 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 2360 | 0.100 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2024 | 76 | 0.060 |
Why?
|
| bcl-X Protein | 1 | 2023 | 52 | 0.060 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2023 | 35 | 0.060 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 78 | 0.060 |
Why?
|
| Philadelphia Chromosome | 1 | 2022 | 38 | 0.050 |
Why?
|
| Retreatment | 1 | 2022 | 107 | 0.050 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2022 | 52 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 189 | 0.050 |
Why?
|
| Mutation | 2 | 2023 | 3968 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2024 | 300 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2023 | 233 | 0.050 |
Why?
|
| Germ Cells | 1 | 2022 | 126 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2022 | 280 | 0.050 |
Why?
|
| Transplantation Conditioning | 1 | 2023 | 373 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2023 | 639 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2023 | 996 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2023 | 592 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 589 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2018 | 93 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2023 | 2426 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1313 | 0.040 |
Why?
|
| Apoptosis | 1 | 2023 | 1683 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 930 | 0.040 |
Why?
|
| Remission Induction | 1 | 2018 | 722 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2018 | 695 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2023 | 3243 | 0.030 |
Why?
|
| Liver | 1 | 2018 | 1230 | 0.030 |
Why?
|
| Child | 1 | 2018 | 6928 | 0.020 |
Why?
|
| Aged | 1 | 2023 | 18423 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 7998 | 0.020 |
Why?
|
| Middle Aged | 1 | 2023 | 25040 | 0.010 |
Why?
|